Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $15.71

Shares of Altimmune, Inc. (NASDAQ:ALT) have been given an average recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $15.7143.

ALT has been the subject of several analyst reports. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th. Leerink Partners began coverage on shares of Altimmune in a report on Monday, June 22nd. They set an “outperform” rating and a $10.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $20.00 target price (down from $25.00) on shares of Altimmune in a research report on Monday, May 18th. Finally, Citizens Jmp reduced their price target on Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP increased its position in shares of Altimmune by 356.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after buying an additional 1,559,562 shares in the last quarter. State Street Corp lifted its holdings in Altimmune by 42.2% during the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock worth $18,482,000 after acquiring an additional 1,518,448 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Altimmune by 23.3% during the third quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after acquiring an additional 1,206,514 shares in the last quarter. Nuveen LLC grew its stake in Altimmune by 514.9% in the fourth quarter. Nuveen LLC now owns 1,244,211 shares of the company’s stock valued at $4,492,000 after acquiring an additional 1,041,856 shares during the period. Finally, Marshall Wace LLP acquired a new position in Altimmune in the fourth quarter valued at about $3,331,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Trading Up 0.7%

Shares of ALT opened at $2.87 on Friday. The stock’s fifty day simple moving average is $2.90 and its 200-day simple moving average is $3.57. The firm has a market capitalization of $558.14 million, a PE ratio of -3.09 and a beta of 0.25. Altimmune has a 12-month low of $2.56 and a 12-month high of $6.44. The company has a quick ratio of 29.56, a current ratio of 29.56 and a debt-to-equity ratio of 0.12.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. As a group, research analysts predict that Altimmune will post -0.64 earnings per share for the current year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.